OCULAR THERAPEUTIX INC (OCUL) — insider trading
Health Care · NASDAQ
OCULAR THERAPEUTIX INC (OCUL) has 32 reported SEC Form 4 insider transactions in our data, including 12 open-market sales among the most recent 32 (latest 2026-10-02).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Kaiser Peter | Officer (Chief Development Officer) | Open-market sale | 9,990 | $7.05 | $70.4K | Form 4 |
| 2026-10-02 | Heier Jeffrey S. | Officer (Chief Scientific Officer) | Open-market sale | 10,869 | $7.05 | $76.6K | Form 4 |
| 2026-08-31 | Notman Donald | Officer (Chief Operating Officer) | Open-market sale | 1,099 | $10.24 | $11.3K | Form 4 |
| 2026-08-25 | Dugel Pravin | Director, Officer (See Remarks) | Bona fide gift | 50,092 | — | $0 | Form 4 |
| 2026-08-25 | Dugel Pravin | Director, Officer (See Remarks) | Bona fide gift | 50,092 | — | $0 | Form 4 |
| 2026-08-24 | Dugel Pravin | Director, Officer (See Remarks) | Open-market sale | 21,649 | $10.77 | $233.2K | Form 4 |
| 2026-08-24 | Heier Jeffrey S. | Officer (Chief Scientific Officer) | Open-market sale | 3,296 | $10.78 | $35.5K | Form 4 |
| 2026-08-24 | Nayak Sanjay | Officer (Chief Strategy Officer) | Open-market sale | 1,897 | $10.78 | $20.4K | Form 4 |
| 2026-08-24 | Kaiser Peter | Officer (Chief Development Officer) | Open-market sale | 3,035 | $10.77 | $32.7K | Form 4 |
| 2026-06-16 | Dugel Pravin | Director, Officer (See Remarks) | Bona fide gift | 50,092 | — | $0 | Form 4 |
| 2026-06-16 | Dugel Pravin | Director, Officer (See Remarks) | Bona fide gift | 50,092 | — | $0 | Form 4 |
| 2026-06-10 | Williams Leslie J. | Director | Grant / award / vesting (derivative) | 44,000 | — | $0 | Form 4 |
| 2026-06-10 | Williams Leslie J. | Director | Grant / award / vesting | 14,000 | — | $0 | Form 4 |
| 2026-06-10 | RAINES MERILEE | Director | Grant / award / vesting (derivative) | 44,000 | — | $0 | Form 4 |
| 2026-06-10 | RAINES MERILEE | Director | Grant / award / vesting | 14,000 | — | $0 | Form 4 |
| 2026-06-10 | LINDSTROM RICHARD L MD | Director | Grant / award / vesting (derivative) | 44,000 | — | $0 | Form 4 |
| 2026-06-10 | LINDSTROM RICHARD L MD | Director | Grant / award / vesting | 14,000 | — | $0 | Form 4 |
| 2026-06-10 | Hong Seung Suh | Director | Grant / award / vesting (derivative) | 44,000 | — | $0 | Form 4 |
| 2026-06-10 | Hong Seung Suh | Director | Grant / award / vesting | 14,000 | — | $0 | Form 4 |
| 2026-06-10 | Robins Jason Shand | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 14,024 | — | $0 | Form 4 |
| 2026-06-10 | Robins Jason Shand | Officer (Chief Financial Officer) | Grant / award / vesting | 15,441 | — | $0 | Form 4 |
| 2026-06-10 | Graves Adrienne L | Director | Grant / award / vesting (derivative) | 44,000 | — | $0 | Form 4 |
| 2026-06-10 | Graves Adrienne L | Director | Grant / award / vesting | 14,000 | — | $0 | Form 4 |
| 2026-06-10 | Warden Charles M | Director | Grant / award / vesting (derivative) | 44,000 | — | $0 | Form 4 |
| 2026-06-10 | Warden Charles M | Director | Grant / award / vesting | 14,000 | — | $0 | Form 4 |
| 2026-06-03 | Waheed Nadia | Officer (Chief Medical Officer) | Open-market sale | 14,828 | $8.27 | $122.6K | Form 4 |
| 2026-05-28 | Dugel Pravin | Director, Officer (See Remarks) | Bona fide gift | 394,696 | — | $0 | Form 4 |
| 2026-05-28 | Dugel Pravin | Director, Officer (See Remarks) | Bona fide gift | 394,696 | — | $0 | Form 4 |
| 2026-05-26 | Nayak Sanjay | Officer (Chief Strategy Officer) | Open-market sale | 1,858 | $8.20 | $15.2K | Form 4 |
| 2026-05-26 | Heier Jeffrey S. | Officer (Chief Scientific Officer) | Open-market sale | 3,018 | $8.20 | $24.7K | Form 4 |
| 2026-05-26 | Kaiser Peter | Officer (Chief Development Officer) | Open-market sale | 2,967 | $8.20 | $24.3K | Form 4 |
| 2026-05-26 | Dugel Pravin | Director, Officer (See Remarks) | Open-market sale | 21,156 | $8.20 | $173.5K | Form 4 |
Ask the chat about OCUL's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: OCULAR THERAPEUTIX INC (OCUL).
Last updated 2026-10-02 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.